دورية أكاديمية
Downregulation of human leukocyte antigen Class I expression: an independent prognostic factor in colorectal cancer
| العنوان: | Downregulation of human leukocyte antigen Class I expression: an independent prognostic factor in colorectal cancer |
|---|---|
| المؤلفون: | Nazemalhosseini-Mojarad, E., Asadzadeh-Aghdaei, H., Mohammadpour, S., Esfahani, A.T., Porhoseingholi, M.A., Molaei, M., Jalali, A., Kuppen, P.J.K., Zali, M.R. |
| المصدر: | Journal of Cancer Research and Therapeutics |
| سنة النشر: | 2020 |
| المجموعة: | Leiden Repository (Leiden University) |
| مصطلحات موضوعية: | Clinicopathological characteristics, colorectal neoplasms, human leukocyte antigen, microsatellite instability, survival analysis |
| الوصف: | Aim: In the present study, we evaluated the clinical prognostic value of human leukocyte antigen (HLA (Class I tumor cell expression in a series of colorectal cancer (CRC) patients and also explored the association of this expression profile with molecular features such as mutation status of KRAS and BRAF, microsatellite stability status, and clinicopathological characteristics of the patients. Patients and Methods: Formalin-fixed paraffin-embedded tumor tissue of 258 CRC patient's sections were immunohistochemically stained and subsequently quantified for HLA Class I expression by the tumor cells. Determination of microsatellite instability (MSI) tumor status was ascertained using mononucleotide repeat microsatellite targets. KRAS and BRAF mutations were screened by polymerase chain reaction (PCR)-sequencing and cast-PCR, respectively. Results: HLA Class I expression was normal in 91 cases (35.3%), downregulated in 119 (46.1%), and loss of expression in 48 (18.6%) cases. Forty (15.5%) tumors were MSI-H (MSH), 49 were MSI-L (19%), and 169 were microsatellite stable (MSS) (65.5%). Thirty-six (14%) and 15 (5.8%) of the patients exhibited mutation in the KRAS and BRAF, respectively. It was found that patients with downregulated expression of HLA Class I were associated with Stage II tumors (P < 0.001) and a MSS tumor status (P < 0.001), while patients with loss of expression were associated with MSH status (P < 0.001). Univariate and multivariate analyses revealed that HLA Class I downregulated expression was an independent prognostic parameter for shorter overall patient survival time (hazard ratio: 1.8, P = 0.003). Conclusions:HLA Class I expression is an independent and sensitive clinical prognostic marker that might be used in CRC patients. ; Surgical oncology |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | https://www.cancerjournal.net/article.asp?issn=0973-1482;year=2020;volume=16;issue=8;spage=165;epage=171;aulast=Nazemalhosseini%2DMojaradTest; lumc-id: 115482846; https://hdl.handle.net/1887/3185312Test |
| DOI: | 10.4103/jcrt.JCRT_429_18 |
| الإتاحة: | https://doi.org/10.4103/jcrt.JCRT_429_18Test https://hdl.handle.net/1887/3185312Test https://www.cancerjournal.net/article.asp?issn=0973-1482;year=2020;volume=16;issue=8;spage=165;epage=171;aulast=Nazemalhosseini%2DMojaradTest |
| رقم الانضمام: | edsbas.E25E190B |
| قاعدة البيانات: | BASE |
| DOI: | 10.4103/jcrt.JCRT_429_18 |
|---|